Please login to the form below

Not currently logged in
Email:
Password:

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line

Latest news

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    basal cell carcinoma in patients not suitable for surgery or radiotherapy. ... in a phase I/II trial in small cell lung cancer (SCLC) patients.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Actelion. USA. sonidegib. Odomzo. basal cell carcinoma. SMO receptor

  • EU green light for Novartis' skin cancer therapy EU green light for Novartis' skin cancer therapy

    EU green light for Novartis' skin cancer therapy. Swiss firm’ s basal cell carcinoma treatment can now be launched across Europe. ... Odomzo (sonidegib) is used to treat locally-advanced basal cell carcinoma - the most common form of skin cancer - in

  • FDA approves four new medicines across multiple areas FDA approves four new medicines across multiple areas

    Skin cancer. Meanwhile, Novartis' Odomzo (sonidegib) has been approved for locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or who are not candidates for surgery

  • Ten new medicines recommended in Europe Ten new medicines recommended in Europe

    Novartis has also received a second recommendation for another cancer drug in the form of Odomzo (sonidegib), which is indicated for the treatment of basal cell carcinoma, the most common - but ... Generic recommendations. Three generic medicines

More from news
Approximately 5 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Curis looks to MedImmune and Takeda for new hires Curis looks to MedImmune and Takeda for new hires

    Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics